Trial reportObstetrics and gynecology2009
Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Trial report in Obstetrics and gynecology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Who cites it
25 citing papers in PubMed, 7 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- The use of progesterone during pregnancy to prevent preterm birth.Saudi medical journal · 2020Pooled it
- Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.The Cochrane database of systematic reviews · 2019Pooled it
- Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.The Cochrane database of systematic reviews · 2017Pooled it
- 17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.BJOG : an international journal of obstetrics and gynaecology · 2016Pooled it
- Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.The Cochrane database of systematic reviews · 2013Pooled it
- Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta-analysis of randomized trials.BMC pregnancy and childbirth · 2012Pooled it
- Preterm birth.BMJ clinical evidence · 2011Pooled it
- Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.American journal of obstetrics and gynecology · 2012Trial
- Challenges in Using Progestin to Prevent Singleton Preterm Births: Current Knowledge and Clinical Advice.International journal of women's health · 2024Review
- Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies - A systematic review and meta-analyses.Frontiers in medicine · 2023Review
- In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.American journal of obstetrics and gynecology · 2022Article
- SMFM Special Statement: State of the science on multifetal gestations: unique considerations and importance.American journal of obstetrics and gynecology · 2019Review
- Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol.Pilot and feasibility studies · 2018Article
- What we have learned about the design of randomized trials in pregnancy.Seminars in perinatology · 2016Review
- What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.Seminars in perinatology · 2016Review
- Pharmacogenomics of preterm birth prevention and treatment.BJOG : an international journal of obstetrics and gynaecology · 2016Review
- Recent advances in the prevention and management of preterm birth.F1000prime reports · 2015Review
- Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.Seminars in perinatology · 2014Review
- Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth.Patient preference and adherence · 2013Article
- Progesterone to prevent preterm birth in twin gestations: what is the next step forward?BJOG : an international journal of obstetrics and gynaecology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveTo assess whether 17 alpha-hydroxyprogesterone caproate reduces the rate of preterm birth in women carrying triplets.
methodsWe performed this randomized, double-blinded, placebo-controlled trial in 14 centers. Healthy women with triplets were randomly assigned to weekly intramuscular injections of either 250 mg of 17 alpha-hydroxyprogesterone caproate or matching placebo, starting at 16-20 weeks and ending at delivery or 35 weeks of gestation. The primary study outcome was delivery or fetal loss before 35 weeks.
resultsOne hundred thirty-four women were assigned, 71 to 17 alpha-hydroxyprogesterone caproate and 63 to placebo; none were lost to follow-up. Baseline demographic data were similar in the two groups. The proportion of women experiencing the primary outcome (a composite of delivery or fetal loss before 35 0/7 weeks) was similar in the two treatment groups: 83% of pregnancies in the 17 alpha-hydroxyprogesterone caproate group and 84% in the placebo group, relative risk 1.0, 95% confidence interval 0.9-1.1. The lack of benefit of 17 alpha-hydroxyprogesterone caproate was evident regardless of the conception method or whether a gestational age cutoff for delivery was set at 32 or 28 weeks.
conclusionTreatment with 17 alpha-hydroxyprogesterone caproate did not reduce the rate of preterm birth in women with triplet gestations. CLINICAL
trial registrationClinicalTrials.gov, www.clinicaltrials.gov, NCT00099164 LEVEL OF EVIDENCE: I.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.